Novavax, Inc. (NVAX)
-NasdaqGS 1.93 
0.01(0.52%) Jun 18, 4:00PM EDT
| Prev Close: | 1.92 |
|---|
| Open: | 1.90 |
|---|
| Bid: | 1.85 x 100 |
|---|
| Ask: | 2.28 x 500 |
|---|
| 1y Target Est: | 4.21 |
|---|
| Beta: | 1.22 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 1.88 - 1.93 |
|---|
| 52wk Range: | 1.25 - 2.77 |
|---|
| Volume: | 609,891 |
|---|
| Avg Vol (3m): | 1,605,930 |
|---|
| Market Cap: | 291.84M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.23 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- NOVAVAX INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, Jun 17)
- Novavax Director Buys 50K Shares and 4 Insider Buys to Noteat Wall St. Cheat Sheet(Fri, Jun 14)
- 1 Biotech And 1 Consumer Goods Company With Recent Intensive Insider Buyingat Seeking Alpha(Thu, Jun 13)
- Monday 6/10 Insider Buying Report: NVAX, CPRTat Forbes(Mon, Jun 10)
- Novavax: A Vaccine Company With Large Long-Term Potentialat Seeking Alpha(Mon, Jun 10)
- U.S. Futures Up After Jobs Newsat The Wall Street Journal(Thu, Jun 6)
- Ciena up sharply on surprise profitoptionMONSTER(Thu, Jun 6)
- Novavax Produces MERS-CoV Vaccine CandidateGlobeNewswire(Thu, Jun 6)
- 4 Healthcare Stock Stories Attracting Attention Todayat Wall St. Cheat Sheet(Tue, Jun 4)
- Novavax Announces Public Offer for All Outstanding Shares of IsconovaGlobeNewswire(Tue, Jun 4)
- NOVAVAX INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Jun 4)
- Will Influenza A H7N9 Generate Opportunities For Pharma?at Seeking Alpha(Tue, May 21)
- Flexion Therapeutics Names Frederick Driscoll Chief Financial OfficerPR Newswire(Mon, May 20)
- NOVAVAX INC FinancialsEDGAR Online Financials(Fri, May 17)
- 6 Superstars For Your Biotech Portfolio: John McCamantat Seeking Alpha(Fri, May 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 13.65 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.26 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.06 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases.
View More